Last reviewed · How we verify
NCT03272919
Chemotherapy Induced Peripheral Neuropathy (CIPN)
NA trial testing Arm 1: Investigational INF in Chemotherapy-induced Peripheral Neuropathy in 44 participants. Completed in 25 May 2022.
25 May 2022
Quick facts
| Lead sponsor | Loma Linda University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 44 |
| Start date | 28 September 2017 |
| Primary completion | 25 May 2022 |
| Estimated completion | 25 May 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Arm 1: Investigational INF
- Arm 2: standardized muscle stretching and strength
Conditions studied
- Chemotherapy-induced Peripheral Neuropathy — all drugs for Chemotherapy-induced Peripheral Neuropathy →
Sponsor
Loma Linda University
Who can join
18 and older, female only, with Chemotherapy-induced Peripheral Neuropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chemotherapy induced peripheral neuropathy (CIPN) is a common side effect of many forms of chemotherapy having a negative impact on the quality of life for cancer survivors due to numbness, decreased sensation, pain (of various intensities in the extremities), gait/balance problems, and difficulty with fine motor skills of the hands and fingers.To date, there are no preventive modalities to mitigate CIPN development.When CIPN becomes intolerable, optimal doses of chemotherapy have to be reduced or discontinued, which may affect a patient's overall survival. Intraneural facilitation (INF) is a technique developed by physical therapists at Loma Linda University after careful study of the structure, pathophysiology and biomechanics of peripheral nerves. The focus of INF is restoration of circulation to an ischemic nerve. INF has been offered to subjects receiving treatment at LLUCC with anecdotal success. The purpose of this study is to evaluate INF as a treatment modality under the rigor of scientific inquiry to determine its effectiveness as a viable treatment option for breast cancer patients with CIPN.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives.
da Costa R, Passos GF, Quintão NLM, Fernandes ES, et al · · 2020 · cited 94× · PMID 32352155 · DOI 10.1111/bph.15086 -
Pharmacological Treatment of Chemotherapy-Induced Neuropathic Pain: PPARγ Agonists as a Promising Tool.
Quintão NLM, Santin JR, Stoeberl LC, Corrêa TP, et al · · 2019 · cited 59× · PMID 31555078 · DOI 10.3389/fnins.2019.00907 -
Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment.
Tymon-Rosario J, Adjei NN, Roque DM, Santin AD. · · 2021 · cited 15× · PMID 34944858 · DOI 10.3390/cancers13246239 -
A Novel Approach of Intraneural Facilitation Versus Standard Physical Therapy for the Prevention of Chemotherapy-Induced Peripheral Neuropathy: A Randomized Controlled Trial.
Hankins J, Bussell M, Gharibvand L, Jeon WJ, et al · · 2026 · PMID 41840756 · DOI 10.1177/15347354251413222
Verify or expand the search:
- PubMed search for NCT03272919
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chemotherapy-induced Peripheral Neuropathy
Currently open trials in the same condition.
- NCT07177820 — VGAIT for Chemotherapy-induced Peripheral Neuropathy · NA · recruiting
- NCT07072468 — Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) · Phase 2 · recruiting
- NCT06389721 — Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy · recruiting
- NCT06405542 — Exercise-based Rehabilitation to Treat Persistent Chemotherapy Induced Peripheral Neuropathy (CIPN) · Phase 1 · active not recruiting
- NCT06162403 — Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longi · NA · recruiting
Other Loma Linda University trials
Trials by the same sponsor.
- NCT07213843 — Combined Circulatory and Dietary Interventions for Neuropathy · NA · not yet recruiting
- NCT07130812 — Blood Flow Restriction Training as a Targeted Intervention for Rowers With Back Pain. · NA · recruiting
- NCT06673342 — Effectiveness of a Nutritional Counseling Tool in Reducing the Amount and Frequency of Sugar Intake · NA · completed
- NCT06445842 — Short-term Circuit Training on Muscle Mass and Quality of Life in Sedentary Postmenopausal Women · NA · recruiting
- NCT07396831 — Necessity of Post-operative Eye Drops · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03272919 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Loma Linda University
- Last refreshed: 10 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03272919.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing